Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ORIC 
Oric Pharmaceuticals Inc (ORIC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ORIC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -64.36% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 392.78M USD | Price to earnings Ratio - | 1Y Target Price 19.08 |
Price to earnings Ratio - | 1Y Target Price 19.08 | ||
Volume (30-day avg) 861932 | Beta 1.25 | 52 Weeks Range 5.25 - 14.67 | Updated Date 04/1/2025 |
52 Weeks Range 5.25 - 14.67 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.83 |
Earnings Date
Report Date 2025-03-10 | When Before Market | Estimate -0.5084 | Actual -0.51 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -33.95% | Return on Equity (TTM) -54.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 142842415 | Price to Sales(TTM) - |
Enterprise Value 142842415 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.13 | Shares Outstanding 71026800 | Shares Floating 46231360 |
Shares Outstanding 71026800 | Shares Floating 46231360 | ||
Percent Insiders 9.44 | Percent Institutions 103.76 |
Analyst Ratings
Rating 4.83 | Target Price 18.73 | Buy 2 | Strong Buy 10 |
Buy 2 | Strong Buy 10 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Oric Pharmaceuticals Inc
Company Overview
History and Background
Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that overcome resistance mechanisms in cancer. Founded in 2014, it is dedicated to research and development in cancer treatment.
Core Business Areas
- Oncology Drug Development: Focuses on developing novel therapies to combat cancer resistance.
Leadership and Structure
The leadership team comprises experienced executives in drug development and oncology. The organizational structure is typical of a clinical-stage biotech company, centered around research and clinical development.
Top Products and Market Share
Key Offerings
- ORIC-114: An investigational EGFR inhibitor designed to overcome resistance mechanisms. Currently in clinical trials. Competitors: Tagrisso (AZN), other EGFR inhibitors.
- ORIC-533: An investigational inhibitor of polycomb repressive complex 2 (PRC2) which is being developed for treatment of multiple myeloma. Competitors: Multiple Myeloma treatments by various companies
Market Dynamics
Industry Overview
The oncology drug development industry is characterized by intense competition, high regulatory hurdles, and significant investment in research and development.
Positioning
Oric is positioned as a company focused on overcoming resistance to existing cancer therapies, a significant unmet need.
Total Addressable Market (TAM)
The global oncology market is estimated to be worth hundreds of billions of dollars. Oric is positioned to address specific resistance mechanisms within subsets of this market.
Upturn SWOT Analysis
Strengths
- Targeted approach to cancer resistance
- Experienced management team
- Promising clinical trial results for lead compounds
- Strong intellectual property portfolio
Weaknesses
- Reliance on clinical trial success
- Limited commercialization experience
- High cash burn rate
- Dependence on financing to fund operations
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through additional drug candidates
- Positive clinical trial outcomes leading to regulatory approval
- Advancements in personalized medicine and targeted therapies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Patent challenges
- Economic downturn impacting funding
Competitors and Market Share
Key Competitors
- AZN
- MRTX
Competitive Landscape
Oric faces competition from established pharmaceutical companies with significant resources and experience in oncology drug development. Oric's advantage lies in its targeted approach to addressing cancer resistance mechanisms.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth is based on pipeline development and clinical trial progress rather than historical revenue.
Future Projections: Future growth depends on clinical trial successes and potential regulatory approvals. Analyst estimates are based on potential market penetration of approved drugs.
Recent Initiatives: Focus on advancing lead compounds through clinical trials and exploring potential partnerships.
Summary
Oric Pharmaceuticals is a clinical-stage biopharmaceutical company with a promising focus on overcoming cancer resistance mechanisms. Its future hinges on the success of its clinical trials. The company faces intense competition from larger, established players, requiring strategic partnerships and efficient resource management to navigate regulatory hurdles and achieve commercial success. Financial performance is currently driven by research and development investments, and shareholder returns are tied to clinical trial outcomes.
Similar Companies
- MRTX
- ARRY
- VRTX
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investing in pharmaceutical companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oric Pharmaceuticals Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2020-04-24 | President, CEO & Director Dr. Jacob M. Chacko M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 115 | Website https://www.oricpharma.com |
Full time employees 115 | Website https://www.oricpharma.com | ||
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. The company develops ORIC-533, an orally bioavailable small molecule inhibitor of CD73; and ORIC-613, a small molecule therapeutic intended to address a mechanism of innate resistance found in a subset of breast cancers. It has clinical development collaboration agreement for a potential Phase 2 study of ORIC-533 in multiple myeloma with Pfizer Inc.; a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.